SECISBP2L: A Potential Drug Target and Biomarker (G9728)

Target Name: SECISBP2L

NCBI ID: G9728

SECISBP2L

SECISBP2L: A Potential Drug Target and Biomarker

SECISBP2L, or Selenocysteine insertion sequence-binding protein 2-like (isoform 1), is a protein that has been identified as a potential drug target and biomarker. The protein is expressed in various tissues and organs, including the brain, heart, lungs, and gastrointestinal tract, and is involved in various cellular processes that are important for maintaining cellular health and function.

SECISBP2L is a member of the SECISBP2 family, which is characterized by the presence of a specific C-terminal region that is involved in protein-protein interactions. The SECISBP2L protein is unique in that it is able to form a stable complex with the protein SREBP2, which is a key regulator of lipid metabolism and has been implicated in various diseases, including heart disease and diabetes.

The ability of SECISBP2L to form a stable complex with SREBP2 suggests that it may be a useful drug target for the treatment of diseases that are characterized by abnormal levels of SREBP2 or disruptions in the balance of SREBP2 signaling. This is because SECISBP2L has been shown to play a role in the regulation of cellular processes that are important for maintaining the health and function of tissues and organs, including the brain.

One of the key functions of SECISBP2L is its role in the regulation of cellular stress responses. During times of stress, cells are able to adapt to the demands on them and make changes to their structure and function in order to cope with the stress. SECISBP2L is involved in this process, and has been shown to help cells adapt to stress by modulating the activity of various signaling pathways.

In addition to its role in stress responses, SECISBP2L is also involved in the regulation of cellular signaling pathways that are important for the development and maintenance of tissues and organs. For example, SECISBP2L has been shown to play a role in the regulation of cell proliferation, and has been shown to promote the growth and survival of various cell types.

The potential drug target for SECISBP2L is its ability to form a stable complex with SREBP2, and the regulation of cellular stress responses and signaling pathways. This suggests that SECISBP2L may be a useful biomarker for the assessment of therapeutic interventions that are aimed at modulating these processes.

In conclusion, SECISBP2L is a protein that has been identified as a potential drug target and biomarker. Its unique ability to form a stable complex with SREBP2 and its role in the regulation of cellular stress responses and signaling pathways suggest that it may be a valuable tool for the development of new therapeutic interventions aimed at modulating these processes. Further research is needed to fully understand the role of SECISBP2L in cellular processes and its potential as a drug target and biomarker.

Protein Name: SECIS Binding Protein 2 Like

Functions: Binds SECIS (Sec insertion sequence) elements present on selenocysteine (Sec) protein mRNAs, but does not promote Sec incorporation into selenoproteins in vitro

The "SECISBP2L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SECISBP2L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets